First described by Novo Nordisk researchers, ipamorelin is notable for its selectivity in stimulating growth hormone release without significantly affecting other pituitary hormones such as ACTH, prolactin, FSH, LH, or TSH in preclinical models
Single-cell analyses reveal the therapeutic effects of ATHENA and its mechanism in a rhabdomyosarcoma patient
This rapid growth brings real pressure to pharma manufacturing, particularly around potency, containment, and operator safety
For compounded tirzepatide, which typically costs significantly less than commercial Mounjaro or Zepbound, the margins can be favorable
Nobody deserves any of these negative feelings
Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine